Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
This opens up a huge market for the company’s Magnezis implants in India
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
The transaction is anticipated to close in the first quarter of 2022
More than 90,000 patients utilise the services daily
The first clinical trial is expected to commence in early 2022 both in Europe and the US
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
A team of experts at Fortis Gurugram conducted 3-dimensional mapping with the help of the new system Carto version 7 to precisely map the source of the arrhythmia. It was detected that the arrhythmia was coming from the conduction system i.e. body’s natural wiring.
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
